Biomarkers of Neuroinflammation Proceedings of a Workshop (2018) / Chapter Skim
Currently Skimming:
7 Potential Mechanisms for Moving Forward
7 Potential Mechanisms for Moving Forward
Pages 51-56
The Chapter Skim interface presents what we've algorithmically identified as the most significant single chunk of text within every page in the chapter.
Select key terms on the right to highlight them within pages of the chapter.
From page 51... ...
from normal individuals as well as those with selected diseases, sharing cells, CSF, and data about candidate biomarkers, would be beneficial to the field (Hyman, Potter)
|
From page 52... ...
Tarek Samad said that in order to meet the above objectives, other challenges will need to be addressed: selecting appropriate disease subpopulations, determining the stage or stages of disease to investigate, selecting appropriate measuring tools, and defining a positive outcome with regard to measuring brain neuroimmune tone. While these gaps suggest a development pathway that focuses on disease biology, Samad said that in order to gain enthusiasm and traction from the pharmaceutical industry, a well defined clinical path forward will be required.
|
From page 53... ...
For example, it is now widely accepted that a systemic biomarker of neuroinflammation, C-reactive protein, can be used to predict response to selective serotonin reuptake inhibitors, so subgrouping patients and assessing their responses to different treatment paradigms could accelerate treatment development, even as research continues to try to understand the cell-mediated immune processes that also contribute to neuroinflammation, he said. Another major concern raised by Samad is how to manage the data already collected, including data that already exist within pharmaceutical companies.
|
From page 54... ...
Such consortia will bring value to the entire field by promoting greater visibility, increasing the power of studies by enabling the enrollment of large numbers of participants, aggregating financial resources as well as the human resources of people with different skill sets, and reducing the risk of investment for individual partners, said Campbell. Eliezer Masliah noted that for several years the National Institute on Aging has been funding studies on CSF and fluid biomarkers conducted by public‒private consortia.
|
From page 55... ...
He described the overall program, which includes the preclinical testing of new molecules contributed by the pharma partners as well as biomarker discovery in clinical studies aimed at exploring whether biomarkers can demonstrate a relationship between peripheral and central inflammation as well as a possible relationship between therapeutic resistance to antidepressants and peripheral inflammation. Ultimately, he said the consortium hopes to take one of the new molecules tested preclinically into an experimental medicine or proof-of-concept study for treatment-resistant depression.
|
From page 56... ...
As summarized in the table, both consortia have separate but complementary projects to develop plasma and CSF biomarkers of neuroinflammation in Alzheimer's disease (AD) and major depressive disorder (MDD)
|
Key Terms
This material may be derived from roughly machine-read images, and so is provided only to facilitate research.
More
information on Chapter Skim is available.